Drugs / Ibuprofen
Ibuprofen
also known as
Motrin · Advil · caldolor · IBU · Brufen · Nurofen · S (+) - Ibuprofen · SST-0225 · +51 more
Small molecule targets PPARG, TAS1R3 via activation / inhibition
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | CALDOLOR | — | 2015-11-20 – 2026-01-23 | fda.gov ↗ |
| Label expansion | US (FDA) | MIDOL LIQUID GELS | — | 2006-03-13 | fda.gov ↗ |
| Approved | EU (EMA) | Pedea | — | 2004-07-28 | europa.eu ↗ |
| Label expansion | US (FDA) | ADVIL LIQUI-GELS | — | 2000-03-16 | fda.gov ↗ |
| Label expansion | US (FDA) | INFANT'S ADVIL | — | 2000-01-12 | fda.gov ↗ |
| Label expansion | US (FDA) | CHILDREN'S MOTRIN | — | 1999-04-15 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | MOTRIN | — | 1976-05-03 – 1995-03-24 | fda.gov ↗ |
| Approved | US (FDA) | MOTRIN | — | 1974-09-19 | fda.gov ↗ |
Trials 364 · started per year
today
US approved 1974
EU approved 2004
1
1
1
1
10
5
8
11
8
13
4
11
12
13
23
17
17
18
15
23
11
21
18
11
20
20
24
12
14
19741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials · 1 missed | ||||||
| Phase 0 | NCT07603934 | Dec 2025 → Aug 2026 overdue | dental pulp necrosis | Cairo University | Recruiting | No outcome recorded |
| Phase 0 | NCT07114198 | Aug 2025 | pulpitis | Inonu University | Completed | No outcome recorded |
| Phase 0 | NCT06514222 | Jul → Aug 2024 overdue | impacted teeth, multiple | University of Sharjah | Active not recruiting | Missed primary |
| Phase 0 | NCT06808529 | Jan → May 2024 | primary dysmenorrhea | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05819619 | Jul 2023 → Apr 2024 | — | Hackensack Meridian Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT05695664 | Aug 2021 → Jan 2022 | — | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| Phase 0 | NCT04612920 | Dec 2020 → Mar 2023 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT03953729 | Apr 2019 → Oct 2021 | anxiety | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 0 | NCT03243032 | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02463383 | Sep 2013 → Oct 2014 | breast cancer | Professor Lars Ove Dragsted | Completed | No outcome recorded |
| Phase 143 trials · 1 met primary | ||||||
| Phase 1 | NCT07824258 | Sep 2026 → Dec 2030 expected | — | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT07632274 | Jun → Sep 2026 overdue | — | HALEON | Recruiting | No outcome recorded |
| Phase 1 | NCT07036861 | Nov 2023 → Apr 2024 | — | Berlin-Chemie Menarini | Completed | No outcome recorded |
| Phase 1 | NCT06077786 | Oct 2023 → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05927922 | Jun 2023 → Jun 2024 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT06247462 | Jun → Sep 2023 | acute kidney injury | University of New Mexico | Completed | No outcome recorded |
| Phase 1 | NCT05341999 | Apr 2022 → Apr 2023 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT05512013 | Feb 2022 → Apr 2023 | bone resorption disease, disease of bone structure | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT05329454 | Dec 2020 → Feb 2021 | chronic pain syndrome | Overseas Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04570644 | Aug 2020 → Jan 2021 | Alzheimer disease | AZTherapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03893175 | May 2019 → Mar 2022 | impacted teeth, multiple | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT05428306 | Oct → Nov 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03639571 | Aug → Oct 2018 | — | Medherant Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03418805 | Dec 2017 → Dec 2020 | — | Overseas Pharmaceuticals, Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03225352 | Aug → Oct 2017 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03103022 | Jun 2017 → Apr 2019 | patent ductus arteriosus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03180879 | Apr → Jun 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | Met primary |
| Phase 1 | NCT03018015 | Sep → Oct 2016 | — | SocraTec R&D GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03184766 | Aug 2016 → Jan 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT02521207 | Jul → Aug 2015 | gastroduodenitis | Oxford Pharmascience Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03497715 | Apr → Jul 2015 | — | Reckitt Benckiser Healthcare (UK) Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02666846 | Mar → May 2015 | — | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02482155 | Feb → Mar 2015 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02233582 | Sep 2014 → Oct 2016 | altitude sickness | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT03429738 | Apr → May 2014 | headache disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01986660 | Oct 2013 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01859377 | May → Jun 2013 | — | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT01771822 | Jan → Feb 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01734759 | Nov 2012 → Jan 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01188317 | Jun 2010 → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01055249 | Jan → Jun 2010 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01064726 | Oct 2009 → Apr 2010 | allergic rhinitis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00867880 | Mar → May 2009 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00411190 | Oct → Dec 2006 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00864526 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864357 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00442585 | Sep 2006 → Oct 2007 | — | Gebro Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00239746 | Oct 2005 → Aug 2009 | Alzheimer disease | National Institute on Aging (NIA) | Unknown | No outcome recorded |
| Phase 1 | NCT00372801 | Aug 2005 → ? | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00833157 | Feb 2005 → Jul 2007 | osteoarthritis, knee | Bispebjerg Hospital | Unknown | Mixed |
| Phase 1 | NCT00921830 | Apr → Jul 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | Mixed |
| Phase 1 | NCT02182960 | Sep → Oct 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06088732 | Mar 2024 → Dec 2026 expected | bipolar depression | Laureate Institute for Brain Research, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05742763 | Nov 2023 → Oct 2024 | osteoarthritis, knee | QC Kinetix LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03528343 | Sep → Dec 2017 | appendicitis | University of Utah | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03184649 | May → Sep 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02602483 | Dec 2015 → Dec 2016 | temporomandibular joint disorder | Spherium Biomed | Completed | No outcome recorded |
| Phase 1/2 | NCT00111046 | Feb 2001 → Feb 2004 | malignant choroid melanoma | Royal Liverpool University Hospital | Unknown | No outcome recorded |
| Phase 242 trials · 4 met primary · 8 missed | ||||||
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT06152796 | Dec 2023 → Sep 2025 | patent ductus arteriosus | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT05842044 | Sep 2023 → Sep 2026 overdue | renal carcinoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT04772781 | Jun 2022 → May 2023 | — | Apsen Farmaceutica S.A. | Completed | No outcome recorded |
| Phase 2 | NCT04676802 | Dec 2021 → Feb 2027 expected | neuropathy, painful, osteoarthritis, hand | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT03792295 | Jul → Dec 2021 | — | Khashayar Vaziri | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04575519 | Mar 2021 → Dec 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Germans Trias i Pujol Research Institute | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT03949478 | Feb 2021 → Jan 2025 | epilepsy | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT04907864 | Jan 2020 → Mar 2022 | biliary tract cancer, colorectal cancer, gastric cancer, lung cancer +1 | Kil Yeon Lee | Unknown | No outcome recorded |
| Phase 2 | NCT04485403 | Sep 2019 → Dec 2021 | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03978767 | Jun 2019 → Jun 2026 | severe pre-eclampsia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03767933 | Apr 2019 → Mar 2023 | musculoskeletal system disorder | University of Alberta | Completed | Missed primary |
| Phase 2 | NCT03399318 | Jan 2019 → Dec 2022 | epilepsy, malaria, parasitemia | University of Rochester | Completed | Met primary |
| Phase 2 | NCT03332524 | Jan 2018 → Sep 2019 | sunburn | Sephoris Pharmaceuticals LLC | Terminated | No outcome recorded |
| Phase 2 | NCT03186638 | May 2017 → Mar 2022 | cancer, cognitive impairment with or without cerebellar ataxia | University of Rochester NCORP Research Base | Completed | Missed primary |
| Phase 2 | NCT02781909 | Sep 2016 → Jan 2019 | tuberculosis | Germans Trias i Pujol Research Institute | Completed | Missed primary |
| Phase 2 | NCT02571543 | Jan 2016 → Aug 2022 | anovulation, pregnancy disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT03055247 | Nov 2015 → Jul 2023 overdue | granulomatous disease, chronic, X-linked | IRCCS San Raffaele | Recruiting | No outcome recorded |
| Phase 2 | NCT02580344 | Oct 2015 → Sep 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02531451 | Sep 2015 → Jun 2016 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT02443142 | May 2015 → Jul 2016 | traumatic brain injury | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02344225 | Jan 2015 → Jun 2018 | retinopathy of prematurity | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02339129 | Nov 2014 → Feb 2015 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02241512 | Sep 2014 → Sep 2018 | acute pancreatitis | University of Texas Southwestern Medical Center | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT02133326 | Mar 2014 → Jan 2017 | impacted teeth, multiple | Tufts University School of Dental Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02006576 | Jan 2014 → Mar 2018 | pulmonary emphysema | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT01958320 | Dec 2013 → Jun 2017 | intestinal perforation, necrotizing enterocolitis, patent ductus arteriosus | University of California, San Francisco | Completed | Missed primary |
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2 | NCT01606527 | Jul → Oct 2012 | altitude sickness | Naval Health Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT01605903 | May 2012 → Feb 2017 | adenoid hypertrophy, tonsillitis | Massachusetts Eye and Ear Infirmary | Completed | Missed primary |
| Phase 2 | NCT01559259 | Apr → Sep 2012 | — | Pfizer | Completed | Met primary |
| Phase 2 | NCT01291654 | Apr 2012 → Dec 2014 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01535079 | Feb → Nov 2012 | acute pharyngitis | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT01496326 | Feb → Aug 2011 | osteoarthritis | BioChemics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01293968 | Nov 2010 → Jan 2011 | aphthous stomatitis | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01070745 | Jun 2010 → Jun 2012 | patent ductus arteriosus | Shaare Zedek Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00913627 | May → Aug 2009 | — | Pfizer | Completed | Met primary |
| Phase 2 | NCT00758836 | Dec 2008 → Aug 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT00644319 | Mar 2007 → Sep 2009 | metastatic malignant neoplasm | Oxford University Hospitals NHS Trust | Unknown | No outcome recorded |
| Phase 2 | NCT00121563 | Jul 2005 → Feb 2006 | — | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 2 | NCT00528658 | Jan 2005 → Dec 2008 | — | Chinese University of Hong Kong | Completed | Missed primary |
| Phase 2 | NCT00240812 | ? → Nov 2002 | enuresis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 2/38 trials · 2 met primary | ||||||
| Phase 2/3 | NCT06046105 | Sep 2023 → Mar 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04414995 | Jun → Nov 2020 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03786029 | Apr → Jun 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03789058 | Apr 2018 → Dec 2021 | impacted teeth, multiple | Jordan University of Science and Technology | Unknown | No outcome recorded |
| Phase 2/3 | NCT03055507 | Apr → Dec 2017 | chronic rhinosinusitis | University of Washington | Completed | Met primary |
| Phase 2/3 | NCT02538237 | Nov 2013 → Aug 2014 | periodontitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2/3 | NCT01988298 | Oct 2013 → Feb 2015 | hypertensive disorder | Complejo Hospitalario Dr. Arnulfo Arias Madrid | Completed | No outcome recorded |
| Phase 2/3 | NCT01243996 | Jun 2008 → May 2010 | patent ductus arteriosus | University of Florence | Completed | Met primary |
| Phase 374 trials · 12 met primary · 7 missed | ||||||
| Phase 3 | NCT07225140 | Oct 2026 → Oct 2027 expected | — | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07682558 | Oct 2026 → Nov 2029 expected | — | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07225634 | Sep 2026 → Mar 2027 expected | — | AFT Pharmaceuticals, Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06686862 | Apr 2025 → Apr 2027 expected | acute myocarditis | National Center for Cardiovascular Research Carlos III | Recruiting | No outcome recorded |
| Phase 3 | NCT06731556 | Dec 2024 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 3 | NCT06531707 | May 2024 → Jan 2025 overdue | common cold | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05081102 | Mar → May 2024 | — | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT06317064 | Mar → Oct 2024 | primary dysmenorrhea | Lahore Medical Research Center, LLP | Completed | No outcome recorded |
| Phase 3 | NCT05013567 | Aug 2022 → May 2023 | musculoskeletal system disorder | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT04813991 | Mar 2022 → Sep 2025 | — | Hackensack Meridian Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05011149 | Jan 2022 → Sep 2024 | patent ductus arteriosus | IWK Health Centre | Unknown | No outcome recorded |
| Phase 3 | NCT05000281 | Sep 2021 → Sep 2024 | — | Major Extremity Trauma Research Consortium | Unknown | No outcome recorded |
| Phase 3 | NCT02904304 | Dec 2020 → Jul 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Suspended | No outcome recorded |
| Phase 3 | NCT04429282 | Jun 2020 | — | Yi Feng, MD | Unknown | No outcome recorded |
| Phase 3 | NCT04157036 | Feb 2020 → Sep 2021 | pulpitis | Walter Reed National Military Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04005755 | Jul 2019 → Jun 2020 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03785756 | Apr 2019 → Feb 2020 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | Met primary |
| Phase 3 | NCT03907176 | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04476069 | Jan → Mar 2019 | — | Princess Nourah Bint Abdulrahman University | Completed | No outcome recorded |
| Phase 3 | NCT03722238 | Dec 2018 → Oct 2019 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT03554018 | Oct 2018 → Sep 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02929589 | Jul 2018 → Aug 2021 | — | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT02839785 | Mar 2017 → Sep 2018 | cerebral palsy | University Hospital, Brest | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04282941 | Feb 2017 → Jan 2020 | patent ductus arteriosus | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 3 | NCT03003000 | Dec 2016 → Sep 2017 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT01938144 | Apr → Nov 2016 | common cold | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT02477007 | Dec 2015 → Nov 2018 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02597634 | Nov 2015 → Oct 2016 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02330926 | Apr 2015 → Apr 2023 | hypoproteinemia, hypercatabolic, neoplasm | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT02294019 | Nov 2014 → May 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02141139 | Sep 2014 → Jan 2016 | breast neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01945034 | Nov 2013 → Feb 2015 | — | Pfizer | Completed | Missed primary |
| Phase 3 | NCT01929031 | Aug 2013 → Mar 2014 | neuropathy, painful, tooth disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT01794923 | Jun 2013 → Mar 2014 | — | Pfizer | Completed | Missed primary |
| Phase 3 | NCT01606319 | Feb 2013 → Apr 2015 | asthma | Milton S. Hershey Medical Center | Completed | Missed primary |
| Phase 3 | NCT01785862 | Feb → Jun 2013 | acute pharyngitis | Pierre Fabre Laboratories | Completed | Met primary |
| Phase 3 | NCT01426971 | Dec 2012 → Jun 2013 | — | Sanofi | Withdrawn | No outcome recorded |
| Phase 3 | NCT02441530 | Nov 2012 → Jan 2013 | primary dysmenorrhea | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 3 | NCT01789606 | Sep 2012 → Jun 2013 | — | Pfizer | Completed | Missed primary |
| Phase 3 | NCT02254525 | May 2012 → Jun 2014 | — | Biomendi S.A.U. | Terminated | No outcome recorded |
| Phase 3 | NCT01680939 | May 2012 → Dec 2013 | obstructive sleep apnea syndrome | Hamilton Health Sciences Corporation | Unknown | Met primary |
| Phase 3 | NCT01630278 | Mar 2012 → Jun 2019 | patent ductus arteriosus | Nantes University Hospital | Completed | Missed primary |
| Phase 3 | NCT01562717 | Feb → Oct 2012 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01563289 | Feb → Jul 2012 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01462370 | Nov 2011 → Jun 2012 | primary dysmenorrhea | Organon and Co | Completed | Met primary |
| Phase 3 | NCT01332253 | Jul 2011 → Jul 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01383486 | Jul → Aug 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01362491 | Jun 2011 → Mar 2012 | — | Pfizer | Completed | Mixed |
| Phase 3 | NCT01266161 | Nov 2010 → Mar 2011 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01172405 | Oct 2010 → Oct 2012 | headache disorder | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01216163 | Oct 2010 → Jan 2011 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01002573 | Jul 2010 → Jun 2013 | — | Cumberland Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01098747 | Apr → Jul 2010 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01035346 | Jan 2010 → May 2011 | infectious disease | Pfizer | Terminated | Missed primary |
| Phase 3 | NCT00997074 | Oct 2009 → Oct 2010 | pregnancy disorder | Sheba Medical Center | Completed | Mixed |
| Phase 3 | NCT00984815 | Sep 2009 → Jul 2011 | complex regional pain syndrome, osteoarthritis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01593163 | May 2009 → Mar 2010 | patent ductus arteriosus | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | Completed | No outcome recorded |
| Phase 3 | NCT01229449 | Jan → Sep 2009 | — | Reckitt Benckiser Inc. | Completed | Met primary |
| Phase 3 | NCT00707057 | Jun → Oct 2008 | — | SCOLR Pharma, Inc. | Completed | Met primary |
| Phase 3 | NCT00631111 | Nov 2007 → Apr 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00606489 | Nov 2007 → May 2009 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00470600 | May 2007 → Sep 2008 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00450216 | Mar 2007 → Aug 2008 | ulcer disease | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00147355 | Nov 2005 → Nov 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00225706 | Oct 2005 → Aug 2007 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00150280 | Oct 2004 → Jul 2005 | neuropathy, painful | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00092755 | Apr → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00269191 | Feb → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00440804 | Dec 2002 → Aug 2005 | patent ductus arteriosus | Farmacon | Completed | No outcome recorded |
| Phase 3 | NCT00243815 | Jun 2002 → Nov 2004 | — | FHI 360 | Completed | No outcome recorded |
| Phase 3 | NCT01131000 | Jun 2002 → Aug 2005 | — | Cumberland Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00485160 | Feb 2002 → Sep 2006 | patent ductus arteriosus | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00000574 | Sep 1990 → Jul 1995 | adult acute respiratory distress syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 4107 trials · 3 met primary · 5 missed | ||||||
| Phase 4 | NCT07571252 | Sep → Dec 2026 expected | — | University of Puerto Rico | Recruiting | No outcome recorded |
| Phase 4 | NCT07687394 | Jul 2026 → Oct 2028 expected | gastric neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07512297 | Apr → Dec 2026 expected | nephrolithiasis, ureterolithiasis | University of Gaziantep | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07459049 | Dec 2025 → Jun 2026 overdue | periodontitis | University of Baghdad | Recruiting | No outcome recorded |
| Phase 4 | NCT07565012 | Oct 2025 → Mar 2026 | periapical periodontitis, pulpitis | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT07424001 | Sep 2025 → Jan 2026 | — | Mehmet Çiğdem | Completed | No outcome recorded |
| Phase 4 | NCT07024199 | Sep 2025 → Jun 2027 expected | acute pancreatitis | Medical University of Warsaw | Recruiting | No outcome recorded |
| Phase 4 | NCT06860711 | Jul 2025 → Jun 2028 expected | chronic kidney disease | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07070050 | May 2025 → May 2026 overdue | — | Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology | Recruiting | No outcome recorded |
| Phase 4 | NCT06757075 | Apr 2025 → Mar 2027 expected | — | Boston University | Recruiting | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06479122 | Oct 2024 → Jun 2026 overdue | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06604598 | Oct → Nov 2024 | nephrolithiasis | Universitas Jenderal Soedirman | Completed | No outcome recorded |
| Phase 4 | NCT06398054 | Oct 2024 → Oct 2026 expected | — | ASST Fatebenefratelli Sacco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06113211 | Oct 2024 → Sep 2026 overdue | disease of bone structure, substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06505148 | Aug 2024 → Aug 2025 overdue | — | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06495632 | Aug 2024 → Jul 2026 overdue | — | Cape Fear Valley Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06478758 | Feb → Apr 2024 | — | Giresun University | Completed | Met primary |
| Phase 4 | NCT07859631 | Jan → May 2024 | — | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT05761015 | Dec 2023 → Apr 2028 expected | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 4 | NCT06061575 | Oct 2023 → Oct 2024 | infectious disease with sepsis, paracetamol poisoning | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT05919745 | Oct 2023 → Dec 2026 expected | — | Marquette University | Recruiting | No outcome recorded |
| Phase 4 | NCT06060236 | Sep 2023 → Sep 2024 | disease of bone structure | Ankara City Hospital Bilkent | Unknown | No outcome recorded |
| Phase 4 | NCT05834569 | Jun 2023 → Jan 2025 | delirium, lung neoplasm | Korea University Guro Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT05575700 | Apr 2023 → Aug 2025 | arthropathy | Naestved Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05602064 | Nov 2022 → Feb 2023 | — | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT05763836 | Nov 2022 → Mar 2023 | supratentorial cancer | Ankara University | Unknown | No outcome recorded |
| Phase 4 | NCT05629494 | Sep 2022 → Mar 2026 overdue | prostate cancer, prostatitis | Albany Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT05512754 | Aug 2022 → Dec 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT05076110 | Apr 2022 → Oct 2025 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05190341 | Mar 2022 → Oct 2024 | female infertility | Madigan Army Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT06232785 | Feb 2022 → Oct 2023 | motion sickness | Second Hospital of Jilin University | Completed | No outcome recorded |
| Phase 4 | NCT06064175 | Jan → Dec 2022 | — | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT04905563 | Jun 2021 → Jan 2024 | — | Le Bonheur Children's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT05479747 | Jun → Dec 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04611529 | Mar 2021 → Jun 2023 | — | Montefiore Medical Center | Completed | Missed primary |
| Phase 4 | NCT04533568 | Sep 2020 → Dec 2021 | migraine without aura | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04334629 | May 2020 → May 2021 | COVID-19, respiratory system disorder | King's College London | Withdrawn | No outcome recorded |
| Phase 4 | NCT04123873 | Mar 2020 → Nov 2022 | arthropathy | Naestved Hospital | Completed | Met primary |
| Phase 4 | NCT02985177 | Jan 2020 → Jul 2021 | — | St. Justine's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05332314 | Nov 2019 → Jan 2024 | — | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT04947566 | Sep 2019 → Feb 2020 | neuropathy, painful | Fatima Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03375593 | Aug 2019 → Oct 2021 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 4 | NCT03861611 | Jul 2019 → Feb 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT06187584 | Apr 2019 → Dec 2023 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT03783702 | Apr 2019 → Jul 2020 | drug dependence, opioid abuse, sinusitis | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03759028 | Feb 2019 → Dec 2027 expected | — | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT03749616 | Jan 2019 → Mar 2022 | — | University of Missouri-Columbia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03918135 | Jan 2019 → Jan 2020 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT04609254 | Dec 2018 → Apr 2020 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT04372264 | Oct 2018 → May 2020 | migraine disorder | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT04102566 | Dec 2017 → Oct 2019 overdue | benign prostatic hyperplasia | Benaroya Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT02583399 | Aug 2017 → Jul 2019 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02932579 | Jul 2017 → Jan 2021 | — | University of Rochester | Terminated | Missed primary Stop: Enrollment |
| Phase 4 | NCT03523988 | May → Jun 2017 | — | University of Washington | Completed | Mixed |
| Phase 4 | NCT02902172 | Mar → Oct 2017 | hypertensive disorder | St. Louis University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03622489 | Mar 2017 → Aug 2018 | — | Wolfson Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02836509 | Sep → Dec 2016 | — | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT03169127 | Apr 2016 → Jul 2018 | impacted teeth, multiple | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02777320 | Mar → Aug 2016 | sciatica | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT01974609 | Mar 2016 → Feb 2022 | carpal tunnel syndrome | Horizon Health Network | Completed | No outcome recorded |
| Phase 4 | NCT02686021 | Feb 2016 → Apr 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02778958 | Jan 2016 → Jan 2017 | morbid obesity | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT03265782 | Jun 2015 → Sep 2017 | patent ductus arteriosus | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT03568721 | Jan 2015 → Mar 2018 | — | Rio de Janeiro State University | Completed | No outcome recorded |
| Phase 4 | NCT02294071 | Dec 2014 → Nov 2015 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 4 | NCT02296840 | Nov 2014 → Nov 2016 | drug allergy, obstructive sleep apnea syndrome, tonsillitis | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT02327338 | Nov 2014 → Feb 2015 | — | Future Sciene Technology | Completed | No outcome recorded |
| Phase 4 | NCT02227316 | Aug 2014 → Sep 2016 | benign neoplasm of corpus uteri | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT02076321 | Jan 2014 → Nov 2016 | — | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01901393 | Jul 2013 → Aug 2014 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01530880 | Oct 2012 → Mar 2016 | — | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT01707251 | Oct 2012 → Mar 2015 | obesity disorder | Jacobi Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01563185 | Apr 2012 → Mar 2015 | juvenile idiopathic arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01488955 | Feb 2012 → Feb 2014 | urinary tract infection | Institute of Application-oriented Research and Clinical Trials GmbH | Completed | Mixed |
| Phase 4 | NCT01514175 | Jan → Dec 2012 | chronic pain syndrome | Culpeper Surgery Center | Unknown | No outcome recorded |
| Phase 4 | NCT01377441 | Sep 2011 → May 2013 | inflammatory disease | NYU Langone Health | Terminated | No outcome recorded |
| Phase 4 | NCT01392378 | Aug 2011 → Jan 2013 | — | Pfizer | Completed | Missed primary |
| Phase 4 | NCT01230411 | Jun 2011 → Jun 2017 | migraine disorder | Thomas Jefferson University | Completed | Missed primary |
| Phase 4 | NCT01334944 | Jun 2011 → Sep 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01334957 | Jun 2011 → Dec 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01235949 | Nov 2010 → Mar 2012 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01756209 | Jan 2010 → Feb 2012 | migraine without aura | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT01066676 | Oct 2009 → Jun 2012 | osteoarthritis | Gebro Pharma GmbH | Completed | No outcome recorded |
| Phase 4 | NCT00961753 | Aug 2009 → Oct 2010 | patent ductus arteriosus | OSF Healthcare System | Terminated | No outcome recorded |
| Phase 4 | NCT00938509 | Jul → Oct 2009 | — | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00921700 | Jun 2009 → Nov 2014 | neuropathy, painful | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00484744 | Jun 2007 → Jan 2008 | — | University of Missouri, Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT00470743 | May 2007 → Jun 2009 | patent ductus arteriosus | KK Women's and Children's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01966172 | Mar 2007 → Aug 2009 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01359020 | Jan 2007 → Mar 2008 | — | Mantecorp Industria Quimica e Farmaceutica Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00317655 | Apr 2006 → Apr 2007 | — | Ferrosan AS | Completed | No outcome recorded |
| Phase 4 | NCT00382083 | Mar → Jun 2006 | breast disorder | Mountain States Tumor and Medical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00267293 | Jan 2006 → Jun 2009 | — | Penn State University | Completed | Met primary |
| Phase 4 | NCT00631514 | Jan 2005 → Sep 2006 | hypertensive disorder | University of Split | Completed | No outcome recorded |
| Phase 4 | NCT00217191 | Sep 2004 → Sep 2006 | patent ductus arteriosus, pulmonary immaturity | Maternite Regionale Universitaire | Completed | No outcome recorded |
| Phase 4 | NCT00565500 | Apr 2003 → Apr 2005 | ischemic disease, osteoarthritis | University of Chieti | Completed | No outcome recorded |
| Phase 4 | NCT00167713 | Apr 2003 → Jan 2004 | — | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00620867 | Oct 2002 → Mar 2003 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00046358 | Sep 2002 → Aug 2005 | Alzheimer disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00145730 | Feb 2002 → May 2004 | osteoarthritis, hip, rheumatoid arthritis | The George Institute | Completed | Missed primary |
| Phase 4 | NCT00281762 | ? → Jan 2007 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT00240825 | ? → Feb 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00240864 | ? → Feb 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00261586 | ? → Mar 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase not applicable74 trials · 1 met primary · 5 missed | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07539961 | Sep 2026 → Dec 2027 expected | calcific tendinitis | University Hospital Dubrava | Not yet recruiting | No outcome recorded |
| — | NCT07610408 | Jun → Sep 2026 | — | Ankara Etlik City Hospital | Completed | No outcome recorded |
| — | NCT07399184 | Feb → Aug 2026 overdue | delirium | Ondokuz Mayıs University | Not yet recruiting | No outcome recorded |
| — | NCT07618494 | Feb → May 2026 | dental pulp disorder | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07374354 | Feb 2026 overdue | — | October University for Modern Sciences and Arts | Recruiting | No outcome recorded |
| — | NCT06696573 | Dec 2024 → Dec 2025 overdue | habitual spontaneous abortion | Le Thi Kieu Trang | Recruiting | No outcome recorded |
| — | NCT06015165 | Sep 2024 → Jun 2025 overdue | — | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07844174 | Sep 2024 → Feb 2025 | primary dysmenorrhea | University of Medicine and Pharmacy at Ho Chi Minh City | Completed | No outcome recorded |
| — | NCT06453291 | Jul 2024 → Apr 2025 overdue | chronic pain syndrome | Iffat Anwar Medical Complex | Recruiting | No outcome recorded |
| — | NCT06937853 | May 2024 → Jul 2025 overdue | — | Ataturk University | Recruiting | No outcome recorded |
| — | NCT06601114 | Apr → Oct 2024 overdue | patent ductus arteriosus | Arooj Khan | Active not recruiting | No outcome recorded |
| — | NCT07125911 | Apr 2024 → Apr 2025 | periapical periodontitis | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06594224 | Mar → Aug 2024 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06174363 | Dec 2023 → Dec 2025 overdue | breast cancer | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06015711 | Aug 2023 → Aug 2026 overdue | substance-related disorder | Ajou University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05983354 | Jun 2023 → Aug 2026 | migraine disorder | Health Sciences North Research Institute | Withdrawn | No outcome recorded |
| — | NCT05685342 | Feb 2023 → Feb 2025 | — | Seoul National University Hospital | Completed | Missed primary |
| — | NCT06188143 | Dec 2022 → Jun 2023 | — | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT05626010 | Nov 2022 → Oct 2023 | thyroid gland disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05366777 | Oct 2022 → Jul 2023 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT05509244 | Sep 2022 → Aug 2023 | female reproductive system disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05878262 | Sep 2022 → Mar 2023 | ankyloglossia, teeth, supernumerary | The Children's Hospital of Zhejiang University School of Medicine | Completed | No outcome recorded |
| — | NCT05248152 | Jan 2022 → Jan 2024 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT06574516 | Nov 2021 → Aug 2022 | — | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT05053009 | Nov 2021 → Oct 2022 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04653506 | Nov 2020 → Jul 2022 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT03868137 | Sep 2020 → May 2022 | pelvis syndrome | Orlando VA Medical Center | Unknown | No outcome recorded |
| — | NCT04523623 | Jul 2020 → Jun 2021 | childhood acute lymphoblastic leukemia | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT04087317 | Jun 2020 → Jun 2022 | postpartum depression, substance-related disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT06291337 | Jun 2020 → Sep 2023 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| — | NCT04382768 | May 2020 → Jan 2021 | COVID-19, severe acute respiratory syndrome | Química Luar SRL | Unknown | No outcome recorded |
| — | NCT04337814 | Dec 2019 → Jun 2022 | — | Aga Khan University Hospital, Pakistan | Completed | No outcome recorded |
| — | NCT04202224 | Oct 2018 → Feb 2019 | — | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| — | NCT03952715 | Apr 2018 → Jul 2019 | — | University of Haifa | Unknown | No outcome recorded |
| — | NCT03352362 | Dec 2017 → Mar 2019 | — | Yonsei University | Completed | Met primary |
| — | NCT03146689 | Aug 2017 → Oct 2018 | osteoarthritis, knee | University of Nottingham | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT02603848 | Feb 2017 → Feb 2024 | — | McMaster University | Unknown | No outcome recorded |
| — | NCT03011567 | Jan 2017 → Oct 2019 | hypertension, pregnancy-induced | MemorialCare Health System | Completed | Missed primary |
| — | NCT02935894 | Nov 2016 → Jun 2017 | — | USDA, Western Human Nutrition Research Center | Completed | No outcome recorded |
| — | NCT02807623 | Sep 2016 → Dec 2018 | immune system disorder | Womack Army Medical Center | Completed | No outcome recorded |
| — | NCT02745925 | Apr 2016 → Dec 2018 | obesity disorder | Swiss Federal Institute of Technology | Completed | No outcome recorded |
| — | NCT05256147 | Aug 2015 → May 2016 | vitiligo | Henry Ford Health System | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02863614 | May 2015 → May 2017 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT02806869 | Jan 2015 → Nov 2016 | — | University of Michigan | Completed | No outcome recorded |
| — | NCT02327234 | Dec 2014 → Apr 2015 | allergic asthma | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT02219698 | Jul 2014 → Jul 2015 | diverticulitis | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT02140970 | May 2014 → Jan 2020 | ureteral obstruction, urolithiasis | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01982799 | Feb 2014 → Sep 2015 | tooth disorder | University of Minnesota | Withdrawn | No outcome recorded Stop: Business |
| — | NCT04227652 | Sep 2013 → Feb 2019 | infectious disease with sepsis | University Hospital Ostrava | Completed | No outcome recorded |
| — | NCT02064894 | Jul 2013 → Jun 2015 | musculoskeletal system disorder | St. Justine's Hospital | Completed | Missed primary |
| — | NCT01837810 | Apr 2013 → Apr 2016 | — | Brooke Army Medical Center | Unknown | No outcome recorded |
| — | NCT01886196 | Apr 2013 → Jul 2014 | muscular atrophy, osteoporosis | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT01666587 | Aug 2012 → Apr 2013 | ischemic disease | University of Essex | Completed | No outcome recorded |
| — | NCT01586299 | Mar 2012 → Jun 2015 | pleuropneumonia | Rabin Medical Center | Unknown | No outcome recorded |
| — | NCT00258791 | Jan → May 2012 | mental disorder | Norwegian University of Science and Technology | Withdrawn | No outcome recorded |
| — | NCT01400737 | Jul 2011 → Jul 2012 | — | Zekai Tahir Burak Women's Health Research and Education Hospital | Unknown | No outcome recorded |
| — | NCT01530217 | Mar → Apr 2011 | pulpitis | Universidade Estadual de Ponta Grossa | Completed | No outcome recorded |
| — | NCT01511887 | Jan → Dec 2011 | patent ductus arteriosus | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
| — | NCT00802685 | Nov 2007 → Aug 2010 | patent ductus arteriosus | University of Miami | Terminated | Missed primary |
| — | NCT00462722 | Jul 2007 → Dec 2011 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01758913 | Feb 2007 → Feb 2012 | patent ductus arteriosus | Taipei Medical University Hospital | Completed | No outcome recorded |
| — | NCT00567528 | May 2006 → Apr 2009 | — | Akron Children's Hospital | Terminated | No outcome recorded |
| — | NCT00389272 | Sep 2005 → Dec 2008 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00239512 | Mar 2005 → Jun 2006 | patent ductus arteriosus | China Medical University Hospital | Terminated | No outcome recorded |
| — | NCT00245375 | Jan → Dec 2005 | gallbladder disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT00219895 | Aug 2004 → Mar 2006 | cystic fibrosis | Ramsey, Bonnie, MD | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | Missed primary |
| — | NCT00520442 | Sep 2003 → Sep 2007 | — | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT00474721 | Nov 2002 → Feb 2004 | — | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00004440 | Aug 1996 → Jun 1999 | cystic fibrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| — | NCT00002276 | — | HIV infectious disease, hemophilia A | University of Pittsburgh | Completed | No outcome recorded |
| Comparator or background therapy412 trials | ||||||
| Phase 0 | NCT06640439 Background | Oct 2024 → Feb 2025 overdue | impacted teeth, multiple | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT07204379 Comparator | Jan → Jul 2023 | — | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 0 | NCT03822962 Comparator | Nov 2020 → May 2023 | opioid abuse, sinusitis | University of Nebraska | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04059172 Comparator | Dec 2019 → Jun 2028 expected | persistent idiopathic facial pain | University of Colorado, Denver | Recruiting | No outcome recorded |
| Show all 412 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2025-10-02 | Cumberland Pharmaceuticals | Regulatory Health Care Notes: Cumberland Pharmaceuticals strikes deals in Mexico, the Middle East cumberlandpharma.com ↗
In a separate deal, Cumberland has received product approval in Mexico is for its injectable ibuprofen pain and fever treatment. |
| 2024-07-16 | Roxane Laboratories | Regulatory Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers for Medicare & Medicaid Services (CMS) hikma.com ↗
The new J-code J0138, which was assigned on July 5, 2024, will be effective October 1, 2024. |
| 2023-08-22 | Reckitt Benckiser Inc. | Results Reckitt research on ‘Ibuprofen, other NSAIDs and COVID‑19’ published in Inflammopharmacology reckitt.com ↗
Our publication, in the peer reviewed academic journal Inflammopharmacology, reviews all the key literature in the field, including our own groundbreaking research, concluding that the scientific evidence overwhelmingly refutes the speculation that ibuprofen worsens outcomes in COVID-19. |
| 2023-05-31 | Cumberland Pharmaceuticals | Regulatory CPIX: A Solid Stock With An Exciting Catalyst cumberlandpharma.com ↗
Caldolor recently received approval from the FDA to allow children as young as 3-months old to be prescribed the treatment, which we believe has large potential given its properties as an IV treatment of fever and given that this is now the only non-opioid product approved to treat pain in infants that is delivered through injection. |
| 2023-05-30 | Cumberland Pharmaceuticals | Regulatory Recent 2023 FDA Approvals cumberlandpharma.com ↗
Caldolor® (ibuprofen; Cumberland Pharmaceuticals) Injection was approved by the FDA for the treatment of pain and fever in pediatric patients 6 months of age and older. |
| 2023-05-30 | Cumberland Pharmaceuticals | Regulatory Caldolor gains FDA nod for infant treatment cumberlandpharma.com ↗
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has approved expanded labeling for Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in infants. |
| 2023-05-04 | AFT Pharmaceuticals, Ltd. | Regulatory US FDA sets PDUFA date for Maxigesic IV® aftpharm.com ↗
AFT Pharmaceuticals today announces the US Food and Drug Administration has set 17 October 2023 as the date by which it expects to respond to AFT’s application to register Maxigesic IV in the US. |
| 2023-04-19 | AFT Pharmaceuticals, Ltd. | Regulatory AFT submits Maxigesic IV® packaging data to the US FDA aftpharm.com ↗
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV. |
| 2023-03-14 | AFT Pharmaceuticals, Ltd. | Regulatory Maxigesic Rapid® tablets gain US FDA approval aftpharm.com ↗
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces the US Food and Drug Administration has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US. |
| 2021-07-14 | AFT Pharmaceuticals, Ltd. | Regulatory Maxigesic® Oral Liquid gets first regulatory approval aftpharm.com ↗
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces that it has successfully gained its first regulatory approval of Maxigesic Oral Liquid in Europe (Italy and Malta) with further regulatory approvals now expected. |
| 2020-11-19 | Cumberland Pharmaceuticals | Results Nashville Medical News – Addressing Opioid Usage in the Hospital Setting cumberlandpharma.com ↗
Recently published literature draws a correlation between the use of Caldolor® (ibuprofen) Injection and a decreased need for opioids in certain patient populations. |
| 2020-09-14 | Cumberland Pharmaceuticals | Results Orthopedics This Week - The Effort to Reduce Opioid Use Gets A Boost From New Drugs cumberlandpharma.com ↗
Thankfully, that list is growing with recent publications supporting a pair of drugs that have been shown to reduce opioid use during and after surgery. |
| 2020-03-02 | GlaxoSmithKline | Regulatory FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States gsk.com ↗
Issued: Warren, US GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. |
| 2019-07-24 | AFT Pharmaceuticals, Ltd. | Regulatory AFT Pharmaceuticals’ achieves first registration of it’s patented painkiller Maxigesic IV® in the pivotal Australian market aftpharm.com ↗
AFT Pharmaceuticals (AFT’) today announces it has successfully registered the intravenous form of its successful Maxigesic’ pain relief medication with Australia’s Therapeutic Goods Administration (TGA). |
| 2017-10-20 | AFT Pharmaceuticals, Ltd. | Results Positive result from large US clinical trial for Maxigesic IV (Intravenous) aftpharm.com ↗
The study has found that Maxigesic IV provides much better pain relief than either paracetamol IV or ibuprofen IV alone in the same doses. |
| 2017-05-19 | AFT Pharmaceuticals, Ltd. | Regulatory Further European approval puts Maxigesic on path to become leading global paracetamol-ibuprofen painkiller aftpharm.com ↗
The company was notified overnight (NZ time) by the European Medicines Agency (EMA) of a decision to approve Maxigesic tablets in Austria, Belgium, Croatia, France, Germany, Luxembourg, Netherlands, Portugal and Spain. |
| 2016-11-13 | Pfizer | Results Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com ↗
The final PRECISION trial results provide statistically strong evidence that cardiovascular risk with approved doses of celecoxib is not greater than that of prescription doses of ibuprofen and naproxen. |
| 2015-05-22 | AFT Pharmaceuticals, Ltd. | Results Australasian company finds major formulation error with cold and flu products aftpharm.com ↗
Ibuprofen was subsequently shown to be non- contributory. |
| 2005-07-19 | Perrigo Company | Regulatory Perrigo Company Announces Approval For Prescription Strength Ibuprofen Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market prescription Ibuprofen Tablets, USP 400 mg, 600 mg and 800 mg. |
| 2005-06-24 | Perrigo Company | Regulatory Perrigo Company Announces Approval for Orange Ibuprofen Tablets perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market over-the- counter (OTC) Orange Ibuprofen Tablets/Caplets USP 200 mg. |
| 2004-10-05 | Perrigo Company | Regulatory Perrigo Company Receives FDA Approval to Market Nicotine Gum and Ibuprofen Oral Suspension perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) nicotine polacrilex gum and prescription ibuprofen oral suspension. |
| 2003-11-14 | Perrigo Company | Regulatory Perrigo Company Announces Approvals to Market Three New Products perrigo.com ↗
The Perrigo Company (NASDAQ: PRGO) today announced that it will begin marketing three new products following U.S. Food and Drug Administration (FDA) approvals. |
All press releases naming this drug 27 releases
Evidence & citations 64 cited values
Every value below carries the sentence it was read from. 784 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ibuprofen | “HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor...” NCT00984815 ↗760“When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ “The primary objective was to investigate the efficiency of protective analgesia using combined effects of sustained release ibuprofen and bupivacaine nerve block in attenuation...” NCT00895843 ↗ “Opioid-Free Multimodal Analgesia will receive preoperative acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg), intraoperative ketamine (0.5 mg/kg IV) and dexamethasone (0.1...” NCT07435493 ↗ “Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included...” NCT05479747 ↗ “IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals...” NCT01291654 ↗ “All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3...” NCT06987838 ↗ “During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.” NCT04294537 ↗ “Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.” NCT00962663 ↗ “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02339129 ↗ “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02597634 ↗ |
| Known as | Advil | “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗11“oral analgesics for headache pain such as acetaminophen (Tylenol) or ibuprofen (Motrin or Advil).” NCT02443142 ↗ “Ibuprofen (also known as Advil or Motrin) is a medication that is known to reduce pain.” NCT01681667 ↗ “24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen” NCT01383486 ↗ “You may know ibuprofen by the name Advil or Motrin.” NCT01938040 ↗ “A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)” NCT05428293 ↗ “ibuprofen (also known as Motrin or Advil)” NCT04905563 ↗ “Pfizer 200 mg caplets (Advil)” NCT01716052 ↗ “Advil Ibuprofen table 200 mg” NCT03418805 ↗ “Ibuprofen (Advil)” NCT03404206 ↗ “Ibuprofen (Advil)” NCT07233733 ↗ |
| Known as | Advil Film Coated | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 2015 |
| Known as | Advil Ibuprofen Immediate-Release Tablet 200 mg | “Advil® Ibuprofen Immediate-Release Tablet 200 mg” NCT03418805 ↗ |
| Known as | Aktren | “one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)” NCT03694587 ↗ |
| Known as | Alivium | “treatment group 02 will ibuprofen (Alivium®).” NCT02409381 ↗ |
| Known as | ALZT-OP1b | “ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)” NCT04570644 ↗ |
| Known as | Brufen | “Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included...” NCT05479747 ↗6“The present study will be conducted in order to assess bioequivalence of the Test product (Ibuprofen 400 mg oral powder) and the Reference product 1 (Brufen 400 mg film-coated...” NCT03018015 ↗ “The study will compare the study drug to an already marketed formulation of prescription strength ibuprofen (Brufen® the reference product)” NCT02521207 ↗ “Group 1: Ibuprofen 400 mg (Abbott Brufen)” NCT07275710 ↗ “Drug: Ibuprofen (Brufen®)” NCT07316660 ↗ “Ibuprofen (Brufen®)” NCT07512297 ↗ “Ibuprofen (Brufen®)” NCT01879371 ↗ |
| Known as | Burana | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01410409 ↗ |
| Known as | caldolor | “OBJECTIVES: To evaluate the efficacy of intravenous (IV) ibuprofen (Caldolor) administration in the management of acute pain in orthopedic trauma patients and to minimize opioid use.” PMID 31929374 ↗ Jul 20208“Caldolor® is an intravenous (IV) formulation of ibuprofen encompassing analgesic, anti-inflammatory and antipyretic (anti-fever) properties.” NCT01297829 ↗ “The aim of this study is to evaluate the preventive effect of intravenous ibuprofen (Caldolor®) on remifentanil-induced hyperalgesia” NCT02243254 ↗ “Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]” NCT05763836 ↗ “ibuprofen (caldolor 10 mg / kg)” NCT03352362 ↗ |
| Known as | Dolormin | “Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.” NCT03180879 ↗ |
| Known as | Dolormin Extra | “400 mg ibuprofen (Dolormin Extra)” NCT03225352 ↗1“Dolormin® extra (Ibuprofen)” NCT02096913 ↗ |
| Known as | Fenbid | “Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.” NCT06322407 ↗ |
| Known as | IBU | “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗7“Current standard care includes the use of oral ibuprofen (IBU), a non-steroidal anti-inflammatory drug (NSAID), for mild-to-moderate MSK-I pain in the ED.” NCT02985177 ↗ “The investigators prefer to use Ibuprofen (IBU) for COX-inhibition in this study.” NCT02884219 ↗ “Ibuprofen (IBU) is an efficacious over-the-counter analgesic/antipyretic” PMID 25526232 ↗ Dec 2014 “Ibuprofen (IBU) 200 mg/ Phenylephrine (PE) 10 mg” NCT01938144 ↗ “5% Topical Ibuprofen (IBU) for Ankle Sprain” NCT01945034 ↗ “Commercial Ibuprofen (IBU) (400 mg)” NCT02320708 ↗ “Ibuprofen (IBU)” NCT04575519 ↗ |
| Known as | IBU sodium | “IBU sodium (IBU(Na)) is a newer, more soluble form that is absorbed faster than standard IBU, leading to more rapid analgesia.” PMID 25526232 ↗ Dec 2014 |
| Known as | IBU(Na) | “A novel, immediate-release tablet formulation of ibuprofen (IBU) sodium dihydrate, Advil Film Coated Tablets (IBUNa), has been developed” PMID 25119511 ↗ May 20151“IBU sodium (IBU(Na)) is a newer, more soluble form that is absorbed faster than standard IBU, leading to more rapid analgesia.” PMID 25526232 ↗ Dec 2014 |
| Known as | IBU-H | “Ibuprofen (IBU-H), a widely used anti-inflammatory, also shows a marked antimicrobial effect” PMID 29772761 ↗ May 2018 |
| Known as | IBUCR | “Ibuprofen CR Tablets 600 mg (IBUCR)” NCT03418805 ↗ |
| Known as | Ibufen-L | “Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42).” NCT04111315 ↗ |
| Known as | Ibuprofen (Advil) | “Ibuprofen (Advil)” NCT01605240 ↗ |
| Known as | ibuprofen (Brufen) | “ibuprofen (Brufen)” NCT04907864 ↗ |
| Known as | Ibuprofen (IBU) | “Ibuprofen (IBU)” NCT04575519 ↗ |
| Known as | Ibuprofen (Nurofen) | “Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)” NCT03497715 ↗ |
| Known as | Ibuprofen (Wockhardt) | “Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)” NCT03497715 ↗ |
| Known as | Ibuprofen 400 mg - Novapharin | “Ibuprofen 400 mg - Novapharin” NCT05971186 ↗ |
| Known as | Ibuprofen B.Braun | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Ibuprofen Controlled-Release Tablet 600 mg | “Ibuprofen Controlled-Release Tablet 600 mg” NCT03418805 ↗ |
| Known as | Ibuprofen extrudate | “Drug: Ibuprofen extrudate” NCT02183012 ↗ |
| Known as | Ibuprofen Kabi | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Ibuprofen lysinate | “Drug: Ibuprofen lysinate” NCT02183012 ↗ |
| Known as | ibuprofen sodium | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 20151“Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.” PMID 25526232 ↗ Dec 2014 |
| Known as | Ibuprofen Syrup | “COTA arm (Ibuprofen Syrup and EMLA Cream)” NCT04337814 ↗ |
| Known as | Ibuprofen-Najo | “When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ |
| Known as | Ibuprofen/Advil/Motrin | “Ibuprofen/Advil/Motrin” NCT02029235 ↗ |
| Known as | Ibuprofene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479165 ↗ |
| Known as | Ibuprophen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01666587 ↗ |
| Known as | Ibuvix | “Ibuvix® - ibuprofen” NCT04637529 ↗ |
| Known as | Intrafen | “400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients” NCT03918135 ↗1“Ibuprofen (Intrafen) 800 mg will be administered intravenously.” NCT03063658 ↗ |
| Known as | Intrafen Flk | “800mg Ibuprofen (Intrafen Flk, Gen drug, Turkey) in 150 ml normal saline given as a slow intravenous infusion over 5 minutes” NCT02836509 ↗ |
| Known as | IVIb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00867880 ↗ |
| Known as | LG-ibuprofen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 2024 |
| Known as | M01A E01 Ibuprofen | “M01A E01 Ibuprofen” NCT00699114 ↗ |
| Known as | Midol IB | “Midol IB” NCT04432597 ↗ |
| Known as | Motrin | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 201514“Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs” NCT00002276 ↗ “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗ “Ibuprofen (Advil, Motrin) is a widely available, cheap, and commonly used over the counter NSAID.” NCT05512754 ↗ “Ibuprofen (also known as Advil or Motrin) is a medication that is known to reduce pain.” NCT01681667 ↗ “800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))” NCT02966288 ↗ “Motrin - also known as ibuprofen 800 mg every 6 hours; not to exceed 3200 mg/day” NCT06113211 ↗ “You may know ibuprofen by the name Advil or Motrin.” NCT01938040 ↗ “ibuprofen (also known as Motrin or Advil)” NCT04905563 ↗ “Ibuprofen (Motrin®, Pfizer S.A. de C.V.)” NCT05428306 ↗ “Tylenol/Motrin” NCT03528343 ↗ |
| Known as | Motrin IB | “reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)” NCT05729555 ↗1“Motrin IB Ibuprofen Tablets 200 mg” NCT03418805 ↗ |
| Known as | Motrin IB Ibuprofen Tablets 200 mg | “Motrin® IB Ibuprofen Tablets 200 mg” NCT03418805 ↗ |
| Known as | Motrin, Advil (Ibuprofen) | “Motrin, Advil (Ibuprofen)” NCT02153177 ↗ |
| Known as | Neoprofen | “Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)” NCT05340582 ↗ |
| Known as | NeoProfen (R) | “ibuprofen l-lysine iv solution (NeoProfen (R) )” NCT00440804 ↗ |
| Known as | nonsteroidal anti-inflammatory drug (NSAID) | “nonsteroidal anti-inflammatory drug (NSAID)” NCT01377441 ↗ |
| Known as | Nurfen | “Those randomized to Group A (active) received the NSAID in the study, which was oral commercially-available Nurfen® syrup containing the NSAID ibuprofen.” NCT04476069 ↗ |
| Known as | Nurofen | “Ibuprofen (Nurofen\*) is known as an effective medication to reduce fever in infectious illnesses and is even considered as superior to paracetamol.” NCT00954200 ↗2“RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.” NCT03180879 ↗ “400 mg ibuprofen(Nurofen)” NCT03225352 ↗ |
| Known as | Nurofen dla dzieci Forte pomarańczowy | “the reference medication (Ibuprofen 4% oral suspension marketed under the trade name Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension)” NCT07036861 ↗ |
| Known as | Nurofen Immedia | “Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules” NCT03184766 ↗1“Ibuprofen (Nurofen Immedia®)” NCT01879371 ↗ |
| Known as | Peinlos | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | S (+) - Ibuprofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04772781 ↗ |
| Known as | Spalt forte | “oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen” NCT03018015 ↗ |
| Known as | SST-0225 | “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02339129 ↗ |
| Known as | standard ibuprofen | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 2015 |
| Known as | VALE-ibuprofen | “OBJECTIVE: Investigate the safety and efficacy of a novel transdermal ibuprofen formulation (VALE®-ibuprofen) containing 10% ibuprofen, compared to a placebo in a randomized,...” PMID 24284856 ↗ Nov 2013 |
| Action | Inhibit | “We tested the hypotheses that a reduction in prostaglandin synthesis by ibuprofen treatment during fasting decreased renal water and sodium excretion.” PMID 21029429 ↗ Oct 2010 |
| Modality | Small molecule | “The NSAID ibuprofen has antiinflammatory and analgesic properties” PMID 19843482 ↗ Sep 2009 |
| Route | Intravenous | “ibuprofen given intravenously every six hours” NCT00000574 ↗ |
| Target | PPARG | “Furthermore, we performed a pilot randomised controlled trial to determine the effect of the PPARG Pro(12)Ala polymorphism and the PPARγ stimulator Ibuprofen on sex-hormone...” PMID 27102200 ↗ Apr 2016 |